Bioventus Inc. (BVS)

Market Cap	415.40M
Revenue (ttm)	567.70M
Net Income (ttm)	-31.29M
Shares Out	66.36M
EPS (ttm)	-0.48
PE Ratio	n/a
Forward PE	8.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	391,050
Open	6.56
Previous Close	6.49
Day's Range	6.26 - 6.56
52-Week Range	6.02 - 14.38
Beta	0.84
Analysts	Strong Buy
Price Target	14.40 (+130.03%)
Earnings Date	Aug 5, 2025

About BVS

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spina...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 11, 2021
• Employees: 930
• Stock Exchange: NASDAQ
• Ticker Symbol: BVS
• Website: https://www.bioventus.com

Financial Performance

In 2024, Bioventus's revenue was $573.28 million, an increase of 11.89% compared to the previous year's $512.35 million. Losses were -$33.54 million, -78.53% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for BVS stock is "Strong Buy." The 12-month stock price target is $14.4, which is an increase of 130.03% from the latest price.

Price Target

$14.4

(130.03% upside)

Analyst Consensus: Strong Buy